FN1 and melanoma: We and others have shown that blocking drivers of relevant heterogeneous phenotypes can improve the outcome of targeted therapy in melanoma (Obenauf et al., 2015; Smith et al., 2017), and our data presented here suggest that blocking FN1‐mediated interactions can interfere with melanoma at various stages of disease progression.